Ocrelizumab: Could Genentech/Roche’s Experimental Drug Be the First Effective Progressive MS Therapy?

Click here to receive MS news via e-mail

Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent a viable therapeutic option for progressive forms of the disease.

Multiple sclerosis (MS), a progressive neurodegenerative disorder, has no cure and is estimated to affect more than 2.3 million people worldwide. Relapsing Multiple Sclerosis is the most common type of MS, affecting approximately 85% of all patients with the disease. Primary progressive MS (PPMS) is characterized by escalating worsening symptoms and affects 1 in every 10 MS patients. No approved treatments currently exist for PPMS.

Ocrelizumab, an investigational, humanized monoclonal antibody was designed to target a selective group of immune cells — CD20-positive B cells — which have been shown to damage myelin, the protective layer that covers neurons and that once destroyed leads to motor function impairment, irreversible neurological disability and paralysis.

The therapy was tested in three major clinical trials – OPERA I, OPERA II and ORATORIO. The OPERA I and OPERA II studies tested ocrelizumab in patients with relapsing MS, which showed increased efficacy in reducing three key markers of disease activity when compared to interferon beta-1a (Rebif®), a well-established MS therapy.

The ORATORIO study focused on patients with PPMS where ocrelizumab significantly reduced disease progression — particularly patients’ disability — for at least 12 weeks (primary endpoint), when compared to a placebo control group. Additionally, ocrelizumab achieved positive results in other parameters (secondary endpoints), including reducing the time required to walk 25 feet, the volume of chronic inflammatory brain lesions and brain volume loss.

RELATED: Multiple Sclerosis News Today To Provide Live, On-Site Coverage Of 31st Annual #ECTRIMS2015 Congress

Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development commented on ocrelizumab’s major breakthrough: “The results of these three pivotal trials have the potential to transform the treatment of MS. Ocrelizumab is the first investigational medicine to significantly reduce disability progression in people with relapsing MS and people with primary progressive MS – a form of MS with no approved treatments. We are eager to work with regulatory authorities to bring this investigational medicine to the MS community as soon as possible.”

Stephen Hauser, M.D., Chair of the Scientific Steering Committee of the OPERA studies and Chair of the Department of Neurology at the University of California San Francisco School of Medicine added, “These results redefine our understanding of MS by highlighting the central role of the B cell. The findings may also encourage the MS community to look more closely at earlier treatment of the disease. Currently, many doctors reserve what are considered highly effective MS medicines until a patient’s disease becomes more advanced. Patients and their doctors need new treatment options that offer the potential for greater efficacy than a standard-of-care interferon with a similar safety profile.”

Xavier Montalban, M.D., Ph.D., Chair of the Scientific Steering Committee of the ORATORIO study and Professor of Neurology and Neuroimmunology at Vall d’Hebron University Hospital and Research Institute, Barcelona, Spain also noted, “This is an important moment for the MS community. For decades, trial after trial has failed to show the benefit of any medicine for people with primary progressive MS. Now, for the first time, we have a positive Phase III study result for people with this debilitating form of the disease.”

Roche will now seek marketing authorization for ocrelizumab in both relapsing MS and PPMS.

Tagged , , , , , , , .

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Click here to receive MS news via e-mail


  1. Missy says:

    So THAT’S why the big guns dropped heir patent challenges against Ampyra – who needs generic dalfampridine anymore? This is great news for MS sufferers.

  2. LYNNE HEAL says:

    NOT one MS drug has ever cured MS and never ever will either . Too many are making profits, shares and commissions from MS drugs alongside very high salarys . Billions upon billions .Awaits for someone to actually realize whats been going on for decades . Asks always how many have died on MS drugs . No one yet has done the data on. R.I.P to everyone whos no longer with us and cannot speak up after sadly passing away on MS drugs

  3. LYNNE HEAL says:

    From 2015. IMPORTANT TO UNDERSTAND—the trials with serious infections and deaths reported were at 52 and 48 weeks.
    The MS trial was ONLY 12 WEEKS.

    There were 6 deaths associated with infections in the RA phase III trial.
    There were 5 deaths associated with serious infections in the Lupus phase III trial.

    HOW MANY MORE DEATHS of MS participants in the trial would be reported if patients on Ocrelizumab were followed for a year, instead of 3 months??!!

Leave a Comment

Your email address will not be published. Required fields are marked *